Autopsy report · NCT02315638

Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.

“Long term safety follow-up no longer required”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 10 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Tacere Therapeutics, Inc.

Sponsor type

Industry

Conditions

Hepatitis C

Participants

9

Sites

1

Countries

United States

Trials that died the same way

• Timing for Removal of Chest Tubes in Adult Cardiac Surgery
  “Safety interim analysis” (65% match in meaning)
• Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
  “New Safety Information” (59% match in meaning)
• A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)
  “Safety Issues” (58% match in meaning)
• Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)
  “Safety-related” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.